Skip to main content
SpringerLink
Log in
Book cover

Practical Guide to Dermatology pp 289–306Cite as

Common Cutaneous Side Effects of Anti-cancer Agents

  • Chapter
  • First Online:

  • 1281 Accesses

Abstract

Cutaneous side effects of anti-cancer agents affecting the skin, hair, nails and mucosa are commonly seen in the in-patient and out-patient settings. Here, we will review the various common cutaneous side effects by chemotherapy type: cytotoxic chemotherapies, EGFR inhibitors , multitargeted small molecule kinase inhibitors , BRAF inhibitors , MEK inhibitors , and checkpoint inhibitors . Some entities are more specific to certain anti-cancer classes such as hand foot syndrome for cytotoxic chemotherapies, papulopustular rashes for EGFR inhibitors , hand-foot skin reaction for multitargeted small molecule kinase inhibitors , and various autoimmune diseases with checkpoint inhibitors .

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Notes

  1. 1.

    Iberri DJ, Kwong BY, Stevens LA, Coutre SE, Kim J, Sabile JM, Advani RH. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol.

  2. 2.

    Stewart J, Bayers S, Vandergriff T. Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis. Am J Dermatopathol. 2018 Feb; 40(2):e28–e29.

  3. 3.

    Dervis E, Ayer M, Akin Belli A, Barut SG. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up. Eur J Dermatol. 2016 Apr 1;26(2):133–7.

  4. 4.

    Penn EH, Chung HJ, Keller M. Imatinib mesylate-induced lichenoid drug eruption. Cutis. 2017 Mar; 99(3):189–192. Review.

  5. 5.

    Al-Dawsari, Najla, et al. “Chapter 20: Histone Deacetylase Inhibitors, Proteasome Inhibitors, Demthylating Agents, Arsenicals, Retinoids.” Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients, by Mario E. Lacouture, Wiley-Blackwell, 2014, pp. 216–217.

  6. 6.

    Gabriel JG, Kapila A, Gonzalez-Estrada A. A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib. J Investig Med High Impact Case Rep. 2017 May 24; 5(2):2324709617711463.

  7. 7.

    de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017 Oct; 102(10):1629–1639. doi: 10.3324/haematol.2017.164103. Epub 2017 Aug 3. Review.

References

  1. National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Nov, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

  2. Cohen PR. Acral erythema: a clinical review. Cutis. 1993;51(3):175–9.

    CAS  PubMed  Google Scholar 

  3. Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med. 1982;97(1):61–2.

    CAS  PubMed  Google Scholar 

  4. Hood AF, Haynes HA. Dermatologic complications. In: Holland JF, editor. Cancer medicine. 4th ed. Baltimore: Williams & Wilkins; 1997.

    Google Scholar 

  5. Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–94.

    PubMed  Google Scholar 

  6. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998;82(5):965–9.

    CAS  PubMed  Google Scholar 

  7. Eich D, Scharffetter-Kochanek K, Eich HT, Tantcheva-Poor I, Krieg T. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol. 2002;25(6):599–602.

    PubMed  Google Scholar 

  8. Ozmen S, Dogru M, Bozkurt C, Kocaoglu AC. Probable cytarabine-induced acral erythema: report of 2 pediatric cases. J Pediatr Hematol Oncol. 2013;35(1):e11–3.

    PubMed  Google Scholar 

  9. Farr KP, Safwat A. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol. 2011;4(1):229–35.

    PubMed  PubMed Central  Google Scholar 

  10. Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, et al. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. Cancer. 2017;123(18):3602–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Wong M, Choo SP, Tan EH. Travel warning with capecitabine. Ann Oncol Off J Eur Soc Med Oncol. 2009;20(7):1281.

    CAS  Google Scholar 

  12. Chavarri-Guerra Y, Soto-Perez-de-Celis E. Images in clinical medicine. Loss of fingerprints. N Engl J Med. 2015;372(16):e22.

    PubMed  Google Scholar 

  13. Al-Ahwal MS. Chemotherapy and fingerprint loss: beyond cosmetic. Oncologist. 2012;17(2):291–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Wheeland RG, Burgdorf WH, Humphrey GB. The flag sign of chemotherapy. Cancer. 1983;51(8):1356–8.

    CAS  PubMed  Google Scholar 

  15. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Derm. 1999;40(3):367–98; (quiz 99–400).

    CAS  PubMed  Google Scholar 

  16. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin N Am. 1986;70(1):187–209.

    CAS  PubMed  Google Scholar 

  17. Baker BW, Wilson CL, Davis AL, Spearing RL, Hart DN, Heaton DC, et al. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth. Bone Marrow Transpl. 1991;7(1):43–7.

    CAS  Google Scholar 

  18. van den Hurk CJ, Breed WP, Nortier JW. Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2012;20(12):3255–60.

    Google Scholar 

  19. Komen MM, Breed WP, Smorenburg CH, van der Ploeg T, Goey SH, van der Hoeven JJ, et al. Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2016;24(6):2735–41.

    Google Scholar 

  20. Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist. 2013;18(7):885–91.

    PubMed  PubMed Central  Google Scholar 

  21. Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, et al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(11):2879–84.

    CAS  Google Scholar 

  22. Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol. 2010;63(2):333–6.

    PubMed  Google Scholar 

  23. Fonia A, Cota C, Setterfield JF, Goldberg LJ, Fenton DA, Stefanato CM. Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients. J Am Acad Dermatol. 2017;76(5):948–57.

    CAS  PubMed  Google Scholar 

  24. Chen M, Crowson AN, Woofter M, Luca MB, Magro CM. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004;31(4):818–20.

    PubMed  Google Scholar 

  25. Marchetti MA, Noland MM, Dillon PM, Greer KE. Taxane associated subacute cutaneous lupus erythematosus. Dermatol Online J. 2013;19(8):19259.

    CAS  PubMed  Google Scholar 

  26. Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol. 2007;34(7):473–6.

    PubMed  Google Scholar 

  27. Weger W, Kranke B, Gerger A, Salmhofer W, Aberer E. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol. 2008;59(2 Suppl 1):S4–6.

    PubMed  Google Scholar 

  28. Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol. 2010;146(10):1113–6.

    PubMed  Google Scholar 

  29. Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013;149(9):1071–5.

    PubMed  Google Scholar 

  30. Passiu G, Cauli A, Atzeni F, Aledda M, Dessole G, Sanna G, et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol. 1999;18(5):422–4.

    CAS  PubMed  Google Scholar 

  31. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl):S73–6.

    PubMed  Google Scholar 

  32. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58(4):545–70.

    PubMed  Google Scholar 

  33. Shenkier T, Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol Off J Am Soc Clin Oncol. 1994;12(2):439.

    CAS  Google Scholar 

  34. Parry BR. Radiation recall induced by tamoxifen. Lancet (London, England). 1992;340(8810):49.

    CAS  Google Scholar 

  35. Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15(11):1227–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. D’Angio GJ, Farber S, Maddock CL. Potentiation of x-ray effects by actinomycin D. Radiology. 1959;73:175–7.

    PubMed  Google Scholar 

  37. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2001;59(3):237–45.

    CAS  Google Scholar 

  38. Schwartz BM, Khuntia D, Kennedy AW, Markman M. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol. 2003;91(2):421–2.

    PubMed  Google Scholar 

  39. Camidge R, Price A. Radiation recall dermatitis may represent the Koebner phenomenon. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(19):4130; author reply.

    PubMed  Google Scholar 

  40. Gzell CE, Carroll SL, Suchowerska N, Beith J, Tan K, Scolyer RA. Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin. Cancer Invest. 2009;27(4):397–401.

    PubMed  Google Scholar 

  41. Korbitz BC, Reiquam CW. Busulfan in chronic granulocytic leukemia, a spectrum of clinical considerations. Clin Med. 1969;76(16).

    Google Scholar 

  42. Bandini G, Belardinelli A, Rosti G, Calori E, Motta MR, Rizzi S, et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transpl. 1994;13(5):577–81.

    CAS  Google Scholar 

  43. Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol. 1983;9(5):645–63.

    CAS  PubMed  Google Scholar 

  44. Hendrix JD Jr, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol. 1992;31(7):458–66.

    PubMed  Google Scholar 

  45. Issaivanan M, Mitu PS, Manisha C, Praveen K. Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review. Pediatr Dermatol. 2004;21(2):124–7.

    CAS  PubMed  Google Scholar 

  46. Aste N, Fumo G, Contu F, Aste N, Biggio P. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol. 2002;47(1):146–7.

    PubMed  Google Scholar 

  47. Al-Lamki Z, Pearson P, Jaffe N. Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer. 1996;77(8):1578–81.

    CAS  PubMed  Google Scholar 

  48. Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol. 2006;33(1):86–97.

    CAS  PubMed  Google Scholar 

  49. Schulte-Huermann P, Zumdick M, Ruzicka T. Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma. Dermatology (Basel, Switzerland). 1995;191(1):65–7.

    CAS  Google Scholar 

  50. Baselga E, Drolet BA, Casper J, Esterly NB. Chemotherapy-associated supravenous hyperpigmentation. Dermatology (Basel, Switzerland). 1996;192(4):384–5.

    CAS  Google Scholar 

  51. Todkill D, Taibjee S, Borg A, Gee BC. Flagellate erythema due to bleomycin. Br J Haematol. 2008;142(6):857.

    CAS  PubMed  Google Scholar 

  52. Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol. 1994;131(5):700–2.

    CAS  PubMed  Google Scholar 

  53. Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases. 2016;4(12):390–400.

    PubMed  PubMed Central  Google Scholar 

  54. Masson Regnault M, Gadaud N, Boulinguez S, Tournier E, Lamant L, Gladieff L, et al. Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature. Dermatology (Basel, Switzerland). 2015;231(4):312–8.

    CAS  Google Scholar 

  55. Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181–9.

    CAS  PubMed  Google Scholar 

  56. Sibaud V, Fricain JC, Baran R, Robert C. [Pigmentary disorders induced by anticancer agents. part I: chemotherapy]. Annales de dermatologie et de venereologie. 2013;140(3):183–96.

    CAS  PubMed  Google Scholar 

  57. Sibaud V, Leboeuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol EJD. 2016;26(5):427–43.

    PubMed  Google Scholar 

  58. Chapman S, Cohen PR. Transverse leukonychia in patients receiving cancer chemotherapy. South Med J. 1997;90(4):395–8.

    CAS  PubMed  Google Scholar 

  59. Alimonti A, Nardoni C, Papaldo P, Ferretti G, Caleno MP, Carlini P, et al. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res. 2005;25(5):3531–2.

    PubMed  Google Scholar 

  60. Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(19):4424–9.

    Google Scholar 

  61. Scotte F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112(7):1625–31.

    PubMed  Google Scholar 

  62. Gonzalez E, Gonzalez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol. 1996;35(6):871–85; (quiz 86–7).

    PubMed  Google Scholar 

  63. Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: photoallergic and phototoxic reactions. Clin Dermatol. 2016;34(5):571–81.

    PubMed  Google Scholar 

  64. Leroy D, Dompmartin A, Szczurko C. Flutamide photosensitivity. Photodermatol Photoimmunol Photomed. 1996;12(5):216–8.

    CAS  PubMed  Google Scholar 

  65. Usuki A, Funasaka Y, Oka M, Ichihashi M. Tegafur-induced photosensitivity–evaluation of provocation by UVB irradiation. Int J Dermatol. 1997;36(8):604–6.

    CAS  PubMed  Google Scholar 

  66. Fujimoto M, Kikuchi K, Imakado S, Furue M. Photosensitive dermatitis induced by flutamide. Br J Dermatol. 1996;135(3):496–7.

    CAS  PubMed  Google Scholar 

  67. Goldfeder KL, Levin JM, Katz KA, Clarke LE, Loren AW, James WD. Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol. 2007;56(3):494–9.

    PubMed  Google Scholar 

  68. Ee HL, Yosipovitch G. Photo recall phenomenon: an adverse reaction to taxanes. Dermatology (Basel, Switzerland). 2003;207(2):196–8.

    Google Scholar 

  69. Droitcourt C, Le Ho H, Adamski H, Le Gall F, Dupuy A. Docetaxel-induced photo-recall phenomenon. Photodermatol Photoimmunol Photomed. 2012;28(4):222–3.

    PubMed  Google Scholar 

  70. Williams BJ, Roth DJ, Callen JP. Ultraviolet recall associated with etoposide and cyclophosphamide therapy. Clin Exp Dermatol. 1993;18(5):452–3.

    CAS  PubMed  Google Scholar 

  71. Andersen KE, Lindskov R. Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy. Photodermatol. 1984;1(3):129–32.

    CAS  PubMed  Google Scholar 

  72. Badger J, Kang S, Uzieblo A, Srinivas S. Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(28):7224–5.

    PubMed  Google Scholar 

  73. Markman M, Kulp B, Peterson G. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. Gynecol Oncol. 2004;94(2):578–80.

    PubMed  Google Scholar 

  74. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol. 1995;33(4):551–73; (quiz 74-6).

    CAS  PubMed  Google Scholar 

  75. Payne AS, Savarese DMF. Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy 2018, 24 Apr 2018. https://www.uptodate.com/contents/cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy.

  76. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol. 2002;138(1):129–31.

    PubMed  Google Scholar 

  77. Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147(3):598–601.

    PubMed  Google Scholar 

  78. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55(4):657–70.

    PubMed  Google Scholar 

  79. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.

    CAS  PubMed  Google Scholar 

  80. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2006;8(Suppl 1):S7–14.

    CAS  PubMed  Google Scholar 

  81. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(22):5235–46.

    Google Scholar 

  82. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151(1):238–41.

    CAS  PubMed  Google Scholar 

  83. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144(6):1169–76.

    CAS  PubMed  Google Scholar 

  84. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12(7):756–65.

    CAS  PubMed  Google Scholar 

  85. Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009;77(2):120–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Lin WL, Lin WC, Yang JY, Chang YC, Ho HC, Yang LC, et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol Off J Am Soc Clin Oncology. 2008;26(16):2779–80.

    Google Scholar 

  87. Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708–20.

    PubMed  PubMed Central  Google Scholar 

  88. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84(1):23–6.

    CAS  PubMed  Google Scholar 

  89. Nowak AK, Byrne MJ. Cisplatin and gemcitabine in malignant mesothelioma. Ann Oncol Off J Eur Soc Med Oncol. 2005;16(10):1711.

    CAS  Google Scholar 

  90. Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol (Stockholm, Sweden). 2003;42(4):345–6.

    Google Scholar 

  91. Pascual JC, Banuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 2004;151(5):1111–2.

    CAS  PubMed  Google Scholar 

  92. Dainichi T, Tanaka M, Tsuruta N, Furue M, Noda K. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology (Basel, Switzerland). 2003;207(3):324–5.

    Google Scholar 

  93. Severino-Freire M, Sibaud V, Tournier E, Pauwels C, Christol C, Lamant L, et al. Acquired perforating dermatosis associated with sorafenib therapy. J Eur Acad Dermatol Venereol JEADV. 2016;30(2):328–30.

    CAS  PubMed  Google Scholar 

  94. Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820–2.

    PubMed  PubMed Central  Google Scholar 

  95. Jimenez-Gallo D, Albarran-Planelles C, Linares-Barrios M, Martinez-Rodriguez A, Baez-Perea JM. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib. JAMA Dermatol. 2013;149(5):624–6.

    PubMed  Google Scholar 

  96. Ikeda M, Fujita T, Mii S, Tanabe K, Tabata K, Matsumoto K, et al. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42(9):820–4.

    PubMed  Google Scholar 

  97. Lewin J, Farley-Loftus R, Pomeranz MK. Erythema multiforme-like drug reaction to sorafenib. J Drugs Dermatol JDD. 2011;10(12):1462–3.

    CAS  PubMed  Google Scholar 

  98. Pichard DC, Cardones AR, Chu EY, Dahut WL, Kong HH. Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA Dermatol. 2016;152(2):227–8.

    PubMed  PubMed Central  Google Scholar 

  99. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60(2):299–305.

    PubMed  Google Scholar 

  100. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol Off J Eur Soc Med Oncol. 2008;19(11):1955–61.

    CAS  Google Scholar 

  101. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(23):e59–61.

    Google Scholar 

  102. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7(1):20–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  103. Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2007;56(1):171–2.

    PubMed  PubMed Central  Google Scholar 

  104. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008;144(6):779–82.

    CAS  PubMed  Google Scholar 

  105. Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg Off Publ Am Soc Dermatol Surg. 2009;35(11):1766–70.

    CAS  Google Scholar 

  106. Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol. 2009;61(3):522–7.

    CAS  PubMed  Google Scholar 

  107. Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J. Sorafenib-induced multiple eruptive keratoacanthomas. Ann Dermatol Venereol. 2009;136(12):894–7.

    CAS  PubMed  Google Scholar 

  108. Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(10):e266–7.

    Google Scholar 

  109. Dean SM, Zirwas M. A Second Case of Sunitinib-associated Pyoderma Gangrenosum. The Journal of clinical and aesthetic dermatology. 2010;3(8):34–5.

    PubMed  PubMed Central  Google Scholar 

  110. ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159(1):242–3.

    PubMed  Google Scholar 

  111. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (London, England). 2011;378(9807):1931–9.

    CAS  Google Scholar 

  112. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886–92.

    CAS  PubMed  Google Scholar 

  113. Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K, Iwamura M. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Urol Int. 2013;91(4):482–3.

    PubMed  Google Scholar 

  114. Lee JH, Lee JH, Lee JH, Kim SY, Kim GM. Case of sunitinib-induced Stevens-Johnson syndrome. J Dermatol. 2013;40(9):753–4.

    PubMed  Google Scholar 

  115. Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol. 2008;144(1):123–5.

    PubMed  Google Scholar 

  116. Hubiche T, Valenza B, Chevreau C, Fricain JC, Del Giudice P, Sibaud V. Geographic tongue induced by angiogenesis inhibitors. Oncologist. 2013;18(4):e16–7.

    PubMed  PubMed Central  Google Scholar 

  117. Gavrilovic IT, Balagula Y, Rosen AC, Ramaswamy V, Dickler MN, Dunkel IJ, et al. Characteristics of oral mucosal events related to bevacizumab treatment. Oncologist. 2012;17(2):274–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  118. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. Expert Rev Anticancer Ther. 2015;15(1):129–41.

    CAS  PubMed  Google Scholar 

  119. Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011;36(4):344–50.

    CAS  PubMed  Google Scholar 

  120. McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(10):2017–26.

    CAS  Google Scholar 

  121. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24(4):396–400.

    PubMed  Google Scholar 

  122. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res CR. 2010;29:95.

    PubMed  Google Scholar 

  123. Kucharz J, Dumnicka P, Kuzniewski M, Kusnierz-Cabala B, Herman RM, Krzemieniecki K. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study. Tumori. 2015;101(5):555–9.

    CAS  PubMed  Google Scholar 

  124. Nagyivanyi K, Budai B, Biro K, Gyergyay F, Noszek L, Kuronya Z, et al. Synergistic survival: a new phenomenon connected to adverse events of first-line sunitinib treatment in advanced renal cell carcinoma. Clin Genitourin Cancer. 2016;14(4):314–22.

    PubMed  Google Scholar 

  125. Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, et al. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol. 2013;43(10):1023–9.

    PubMed  Google Scholar 

  126. Otsuka T, Eguchi Y, Kawazoe S, Yanagita K, Ario K, Kitahara K, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res Off J Jpn Soc Hepatol. 2012;42(9):879–86.

    CAS  Google Scholar 

  127. Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(12):3137–43.

    CAS  Google Scholar 

  128. Cohen PR, Bedikian AY, Kim KB. Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib. J Clin Aesthet Dermatol. 2013;6(5):27–37.

    PubMed  PubMed Central  Google Scholar 

  129. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England). 2012;380(9839):358–65.

    CAS  Google Scholar 

  130. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  131. Ribas A, Kim KB, Schuchter LM, Gonzalez R, Pavlick AC, Weber JS, et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29. Abstract 8509.

    Google Scholar 

  132. Sinha R, Larkin J, Gore M, Fearfield L. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. Br J Dermatol. 2015;173(4):1024–31.

    CAS  PubMed  Google Scholar 

  133. Ascierto PA, Minor D, Ribas A, Lebbe C, O’Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(26):3205–11.

    CAS  Google Scholar 

  134. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11–8.

    CAS  PubMed  Google Scholar 

  135. Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103–9.

    PubMed  Google Scholar 

  136. Chapman PB, Hauschild A, Robert C, Larkin J, Haanen JB, Ribas A, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(15 suppl):8502.

    Google Scholar 

  137. Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Kefford RF, Thompson JF, et al. Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(8):816–23.

    Google Scholar 

  138. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012;366(5):480–1.

    CAS  PubMed  Google Scholar 

  139. Sammut SJ, Tomson N, Corrie P. Pyogenic granuloma as a cutaneous adverse effect of vemurafenib. N Engl J Med. 2014;371(13):1265–7.

    PubMed  Google Scholar 

  140. Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, et al. Vemurafenib and radiosensitization. JAMA Dermatol. 2013;149(7):855–7.

    PubMed  Google Scholar 

  141. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(6):1691–7.

    CAS  Google Scholar 

  142. Bellon T, Lerma V, Gonzalez-Valle O, Gonzalez Herrada C, de Abajo FJ. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol. 2016;174(3):621–4.

    CAS  PubMed  Google Scholar 

  143. Jeudy G, Dalac-Rat S, Bonniaud B, Hervieu A, Petrella T, Collet E, et al. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. Br J Dermatol. 2015;172(5):1454–5.

    CAS  PubMed  Google Scholar 

  144. Sinha R, Lecamwasam K, Purshouse K, Reed J, Middleton MR, Fearfield L. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol. 2014;170(4):997–9.

    CAS  PubMed  Google Scholar 

  145. Anforth R, Menzies A, Byth K, Carlos G, Chou S, Sharma R, et al. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. J Am Acad Dermatol. 2015;72(5):809–15.e1.

    Google Scholar 

  146. Zelboraf (vemurafenib) prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf.

  147. Piraccini BM, Patrizi A, Fanti PA, Starace M, Bruni F, Melotti B, et al. RASopathic alopecia: hair changes associated with vemurafenib therapy. J Am Acad Dermatol. 2015;72(4):738–41.

    PubMed  Google Scholar 

  148. Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, et al. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol EJD. 2016;26(3):232–9.

    CAS  PubMed  Google Scholar 

  149. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(4):482–9.

    CAS  Google Scholar 

  150. Wada N, Uchi H, Furue M. Case of deep vein thrombosis in a patient with advanced malignant melanoma treated with dabrafenib and trametinib. J Dermatol. 2018.

    Google Scholar 

  151. Prescribing information for Cotellic (cobimetinib). http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf.

  152. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25(3):265–8.

    PubMed  Google Scholar 

  153. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(12):2375–91.

    CAS  Google Scholar 

  154. Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3(1):18–22.

    PubMed  Google Scholar 

  155. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet. 2015:76–83.

    Google Scholar 

  156. Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23(6):498–501.

    PubMed  Google Scholar 

  157. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.

    CAS  PubMed  Google Scholar 

  158. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(7):785–92.

    CAS  Google Scholar 

  159. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(10):1020–30.

    CAS  Google Scholar 

  160. Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017;176(6):1649–52.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Henry Ford Health System, 3031 West Grand Blvd, Suite 800, Detroit, MI, 48202, USA

    Allison Zarbo

  2. Henry Ford Health System, 3031 West Grand Blvd, Suite 800, Detroit, MI, 48202, USA

    Anna Axelson

Authors
  1. Allison Zarbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Axelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Axelson .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

    Henry W. Lim

  2. Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

    Laurie L. Kohen

  3. Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

    Samantha L. Schneider

  4. Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

    Danielle Yeager

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zarbo, A., Axelson, A. (2020). Common Cutaneous Side Effects of Anti-cancer Agents. In: Lim, H., Kohen, L., Schneider, S., Yeager, D. (eds) Practical Guide to Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-18015-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18015-7_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18014-0

  • Online ISBN: 978-3-030-18015-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation